| Pharmacology |
|
| Administration route | ORAL |
| Organism | Pinus maritima (PINACEAE) |
| Citation | BELCARO,G: CESARONE,MR: ERRICHI,S: ZULLI,C: ERRICHI,BM: VINCIGUERRA,G: LEDDA,A: DI RENZO,A: STUARD,S: DUGALL,M: PELLEGRINI,L: ERRICHI,S: GIZZI,G: IPPOLITO,E: RICCI,A: CACCHIO,M: CIPOLLONE,G: RUFFINI,I: FANO,F: HOSOI, M: ROHDEWAL,P:. (2008). TREATMENT OF OSTEOARTHRITIS WITH PYCNOGENOL®. THE SVOS (SAN VALENTINO OSTEO-ARTHROSIS STUDY). EVALUATION OF SIGNS, SYMPTOMS, PHYSICAL PERFORMANCE AND VASCULAR ASPECTS.. 22() |
| Amount utilized | |
| Compound isolated | |
| Disease | DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF 100 MG PYCNOGENOL® DAILY (ORAL CAPSULES) IN A 3 MONTH STUDY IN PATIENTS WITH OSTEOARTHRITIS (OA). OA SYMPTOMS WERE EVALUATEDBY WOMAC SCORES, MOBILITY BY RECORDING THEIR WALKING PERFORMANCE (TREADMILL). TREATMENT (77 PATIENTS) AND PLACEBO GROUP (79) WERE COMPARABLE FOR AGE, SEX DISTRIBUTION, WOMAC SCORES, WALKING DISTANCES AND USE OFANTIINFLAMMATORY DRUGS. THE GLOBAL WOMAC SCORE DECREASED BY 56% (P<<<<< 0.05) IN THE TREATMENT GROUPVERSUS 9.6% IN THE PLACEBO GROUP. WALKING DISTANCE IN THE TREADMILL TEST WAS PROLONGED FROM 68 M AT THE STARTTO 198 M AFTER 3 MONTHS TREATMENT (P<<<<< 0.05), UNDER PLACEBO, FROM 65 M TO 88 M (NS).
THE USE OF DRUGSDECREASED BY 58% IN THE TREATMENT GROUP (P<<<<< 0.05) VERSUS 1% UNDER PLACEBO. GASTROINTESTINAL COMPLICATIONSDECREASED BY 63% IN THE TREATMENT GROUP, BUT ONLY 3% UNDER PLACEBO.
OVERALL, TREATMENT COSTS WERE REDUCEDSIGNIFICANTLY COMPARED WITH PLACEBO. FOOT EDEMA WAS PRESENT IN 76% OF THE PATIENTS OF THE TREATMENT GROUPAT INCLUSION AND IN 79% OF THE CONTROLS. AFTER 3 MONTHS EDEMA DECREASED IN 79% OF PYCNOGENOL PATIENTS(P<<<<< 0.05) VS 1% IN CONTROLS. IN CONCLUSION, PYCNOGENOL OFFERS AN OPTION FOR REDUCTION OF TREATMENT COSTS AND SIDE EFFECTS BY SPARING ANTIINFLAMMATORY DRUGS. |
| Dose amount | 100 MG |
| Number | 2 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |